(Q39356631)

11 September 2017

title

Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines (English)

1 reference

11 September 2017

0 references

neoplastic stem cells

1 reference

1 reference

4

Peter Hau

0 references

Jörg B. Schulz

6

object named as

Jörg B Schulz

1 reference

11 September 2017

Dagmar Beier

1

1 reference

11 September 2017

Beate Schriefer

2

1 reference

11 September 2017

Konstantin Brawanski

3

1 reference

11 September 2017

Peter Hau

4

1 reference

11 September 2017

Joachim Weis

5

1 reference

11 September 2017

Christoph P Beier

7

1 reference

11 September 2017

publication date

29 April 2012

1 reference

Journal of Neuro-Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

109

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

45-52

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Temozolomide preferentially depletes cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Variability and regulation of O6-alkylguanine-DNA alkyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Complications of a temozolomide overdose: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Sensitivity to temozolomide in brain tumor initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

Chemoresistance of glioblastoma cancer stem cells--much more complex than expected

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0878-4

p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22544650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22544650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-012-0878-4

1 reference

11 September 2017

1 reference